259 related articles for article (PubMed ID: 28158429)
1. Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes.
Rocchetti M; Sala L; Dreizehnter L; Crotti L; Sinnecker D; Mura M; Pane LS; Altomare C; Torre E; Mostacciuolo G; Severi S; Porta A; De Ferrari GM; George AL; Schwartz PJ; Gnecchi M; Moretti A; Zaza A
Cardiovasc Res; 2017 Apr; 113(5):531-541. PubMed ID: 28158429
[TBL] [Abstract][Full Text] [Related]
2. Allele-specific ablation rescues electrophysiological abnormalities in a human iPS cell model of long-QT syndrome with a CALM2 mutation.
Yamamoto Y; Makiyama T; Harita T; Sasaki K; Wuriyanghai Y; Hayano M; Nishiuchi S; Kohjitani H; Hirose S; Chen J; Yokoi F; Ishikawa T; Ohno S; Chonabayashi K; Motomura H; Yoshida Y; Horie M; Makita N; Kimura T
Hum Mol Genet; 2017 May; 26(9):1670-1677. PubMed ID: 28335032
[TBL] [Abstract][Full Text] [Related]
3. Human Induced Pluripotent Stem Cell-Derived Engineered Heart Tissue as a Sensitive Test System for QT Prolongation and Arrhythmic Triggers.
Lemoine MD; Krause T; Koivumäki JT; Prondzynski M; Schulze ML; Girdauskas E; Willems S; Hansen A; Eschenhagen T; Christ T
Circ Arrhythm Electrophysiol; 2018 Jul; 11(7):e006035. PubMed ID: 29925535
[TBL] [Abstract][Full Text] [Related]
4. Arrhythmogenic calmodulin mutations disrupt intracellular cardiomyocyte Ca2+ regulation by distinct mechanisms.
Yin G; Hassan F; Haroun AR; Murphy LL; Crotti L; Schwartz PJ; George AL; Satin J
J Am Heart Assoc; 2014 Jun; 3(3):e000996. PubMed ID: 24958779
[TBL] [Abstract][Full Text] [Related]
5. Human-induced pluripotent stem cell-derived cardiomyocytes from cardiac progenitor cells: effects of selective ion channel blockade.
Altomare C; Pianezzi E; Cervio E; Bolis S; Biemmi V; Benzoni P; Camici GG; Moccetti T; Barile L; Vassalli G
Europace; 2016 Dec; 18(suppl 4):iv67-iv76. PubMed ID: 28011833
[TBL] [Abstract][Full Text] [Related]
6. Electrical dysfunctions in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with an arrhythmogenic right ventricular cardiomyopathy.
El-Battrawy I; Zhao Z; Lan H; Cyganek L; Tombers C; Li X; Buljubasic F; Lang S; Tiburcy M; Zimmermann WH; Utikal J; Wieland T; Borggrefe M; Zhou XB; Akin I
Europace; 2018 Jun; 20(FI1):f46-f56. PubMed ID: 29566126
[TBL] [Abstract][Full Text] [Related]
7. Anti-arrhythmic potential of the late sodium current inhibitor GS-458967 in murine Scn5a-1798insD+/- and human SCN5A-1795insD+/- iPSC-derived cardiomyocytes.
Portero V; Casini S; Hoekstra M; Verkerk AO; Mengarelli I; Belardinelli L; Rajamani S; Wilde AAM; Bezzina CR; Veldkamp MW; Remme CA
Cardiovasc Res; 2017 Jun; 113(7):829-838. PubMed ID: 28430892
[TBL] [Abstract][Full Text] [Related]
8. NOS1AP polymorphisms reduce NOS1 activity and interact with prolonged repolarization in arrhythmogenesis.
Ronchi C; Bernardi J; Mura M; Stefanello M; Badone B; Rocchetti M; Crotti L; Brink P; Schwartz PJ; Gnecchi M; Zaza A
Cardiovasc Res; 2021 Jan; 117(2):472-483. PubMed ID: 32061134
[TBL] [Abstract][Full Text] [Related]
9. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.
Matsa E; Rajamohan D; Dick E; Young L; Mellor I; Staniforth A; Denning C
Eur Heart J; 2011 Apr; 32(8):952-62. PubMed ID: 21367833
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the CACNA1C-R518C Missense Mutation in the Pathobiology of Long-QT Syndrome Using Human Induced Pluripotent Stem Cell Cardiomyocytes Shows Action Potential Prolongation and L-Type Calcium Channel Perturbation.
Estes SI; Ye D; Zhou W; Dotzler SM; Tester DJ; Bos JM; Kim CSJ; Ackerman MJ
Circ Genom Precis Med; 2019 Aug; 12(8):e002534. PubMed ID: 31430211
[TBL] [Abstract][Full Text] [Related]
11. Novel calmodulin mutations associated with congenital long QT syndrome affect calcium current in human cardiomyocytes.
Pipilas DC; Johnson CN; Webster G; Schlaepfer J; Fellmann F; Sekarski N; Wren LM; Ogorodnik KV; Chazin DM; Chazin WJ; Crotti L; Bhuiyan ZA; George AL
Heart Rhythm; 2016 Oct; 13(10):2012-9. PubMed ID: 27374306
[TBL] [Abstract][Full Text] [Related]
12. Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
El-Battrawy I; Lan H; Cyganek L; Zhao Z; Li X; Buljubasic F; Lang S; Yücel G; Sattler K; Zimmermann WH; Utikal J; Wieland T; Ravens U; Borggrefe M; Zhou XB; Akin I
J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29574456
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach.
Paci M; Passini E; Severi S; Hyttinen J; Rodriguez B
Heart Rhythm; 2017 Nov; 14(11):1704-1712. PubMed ID: 28756098
[TBL] [Abstract][Full Text] [Related]
14. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells.
Ma D; Wei H; Zhao Y; Lu J; Li G; Sahib NB; Tan TH; Wong KY; Shim W; Wong P; Cook SA; Liew R
Int J Cardiol; 2013 Oct; 168(6):5277-86. PubMed ID: 23998552
[TBL] [Abstract][Full Text] [Related]
15. Tbx5 variants disrupt Nav1.5 function differently in patients diagnosed with Brugada or Long QT Syndrome.
Nieto-Marín P; Tinaquero D; Utrilla RG; Cebrián J; González-Guerra A; Crespo-García T; Cámara-Checa A; Rubio-Alarcón M; Dago M; Alfayate S; Filgueiras-Rama D; Peinado R; López-Sendón JL; Jalife J; Tamargo J; Bernal JA; Caballero R; Delpón E;
Cardiovasc Res; 2022 Mar; 118(4):1046-1060. PubMed ID: 33576403
[TBL] [Abstract][Full Text] [Related]
16. Large-Scale Simulation of the Phenotypical Variability Induced by Loss-of-Function Long QT Mutations in Human Induced Pluripotent Stem Cell Cardiomyocytes.
Paci M; Casini S; Bellin M; Hyttinen J; Severi S
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30428582
[TBL] [Abstract][Full Text] [Related]
17. Repolarization instability and arrhythmia by IKr block in single human-induced pluripotent stem cell-derived cardiomyocytes and 2D monolayers.
Altrocchi C; de Korte T; Bernardi J; Spätjens RLHMG; Braam SR; Heijman J; Zaza A; Volders PGA
Europace; 2020 Sep; 22(9):1431-1441. PubMed ID: 32770183
[TBL] [Abstract][Full Text] [Related]
18. A Precision Medicine Approach to the Rescue of Function on Malignant Calmodulinopathic Long-QT Syndrome.
Limpitikul WB; Dick IE; Tester DJ; Boczek NJ; Limphong P; Yang W; Choi MH; Babich J; DiSilvestre D; Kanter RJ; Tomaselli GF; Ackerman MJ; Yue DT
Circ Res; 2017 Jan; 120(1):39-48. PubMed ID: 27765793
[TBL] [Abstract][Full Text] [Related]
19. The Arrhythmogenic Calmodulin p.Phe142Leu Mutation Impairs C-domain Ca2+ Binding but Not Calmodulin-dependent Inhibition of the Cardiac Ryanodine Receptor.
Søndergaard MT; Liu Y; Larsen KT; Nani A; Tian X; Holt C; Wang R; Wimmer R; Van Petegem F; Fill M; Chen SR; Overgaard MT
J Biol Chem; 2017 Jan; 292(4):1385-1395. PubMed ID: 27927985
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes.
Ma D; Wei H; Lu J; Huang D; Liu Z; Loh LJ; Islam O; Liew R; Shim W; Cook SA
Stem Cell Res Ther; 2015 Mar; 6(1):39. PubMed ID: 25889101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
